Back to Search
Start Over
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy
- Source :
- Circulation. Heart failure. 9(9)
- Publication Year :
- 2016
-
Abstract
- Background— In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitor enalapril in patients with heart failure and reduced ejection fraction. We examined whether this benefit was consistent irrespective of background therapy. Methods and Results— We examined the effect of study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no), and defibrillating device (implanted defibrillating device, yes/no). We also examined the effect of study drug according to β-blocker dose (≥50% and P P Conclusions— The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless of background therapy and irrespective of previous coronary revascularization or β-blocker dose. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01035255.
- Subjects :
- Time Factors
medicine.medical_treatment
Tetrazoles
Digitalis
Angiotensin-Converting Enzyme Inhibitors
030204 cardiovascular system & hematology
Pharmacology
Sacubitril
0302 clinical medicine
Enalapril
Myocardial Revascularization
030212 general & internal medicine
Prospective Studies
Diuretics
Ejection fraction
biology
Aminobutyrates
Defibrillators, Implantable
Drug Combinations
Treatment Outcome
Valsartan
Cardiology
Drug Therapy, Combination
Cardiology and Cardiovascular Medicine
medicine.drug
medicine.medical_specialty
Cardiotonic Agents
Adrenergic beta-Antagonists
Electric Countershock
Revascularization
neprilysin
03 medical and health sciences
Angiotensin Receptor Antagonists
Double-Blind Method
Internal medicine
medicine
Humans
cardiovascular diseases
Proportional Hazards Models
Heart Failure
sacubrtril/valsartan
business.industry
Biphenyl Compounds
biology.organism_classification
medicine.disease
Clinical trial
Heart failure
business
Sacubitril, Valsartan
Subjects
Details
- ISSN :
- 19413297 and 19413289
- Volume :
- 9
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- Circulation. Heart failure
- Accession number :
- edsair.doi.dedup.....9b52b038de35502e91f2aecace5b4905